{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:52:16Z","timestamp":1783122736467,"version":"3.54.6"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.tips.2015.09.006","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T19:35:54Z","timestamp":1445715354000},"page":"799-801","source":"Crossref","is-referenced-by-count":34,"title":["PML: The Dark Side of Immunotherapy in Multiple Sclerosis"],"prefix":"10.1016","volume":"36","author":[{"given":"Clemens","family":"Warnke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2015.09.006_bib0085","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/jnnp-2013-307207","article-title":"Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience","volume":"85","author":"Burman","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2015.09.006_bib0090","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1007\/s00702-013-1055-4","article-title":"Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards","volume":"120","author":"Warnke","year":"2013","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.tips.2015.09.006_bib0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.tips.2015.09.006_bib0100","doi-asserted-by":"crossref","DOI":"10.1002\/ana.24471","article-title":"Progressive hemiparesis in a psoriasis patient treated with dimethyl fumarate","author":"Bartsch","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2015.09.006_bib0105","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tips.2015.09.006_bib0110","article-title":"Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail","author":"Van Schependom","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.tips.2015.09.006_bib0115","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.tips.2015.09.006_bib0120","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneurol.2010.161","article-title":"Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?","volume":"67","author":"Warnke","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.tips.2015.09.006_bib0125","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0b013e3182a84101","article-title":"Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis","volume":"15","author":"Warnke","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2015.09.006_bib0130","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF","volume":"21","author":"Warnke","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.tips.2015.09.006_bib0135","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMc1214233","article-title":"JC viremia in natalizumab-treated patients with multiple sclerosis","volume":"6","author":"Major","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2015.09.006_bib0140","doi-asserted-by":"crossref","first-page":"e1004084","DOI":"10.1371\/journal.ppat.1004084","article-title":"JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants","volume":"10","author":"Sundqvist","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tips.2015.09.006_bib0145","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2015.09.006_bib0150","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2015.09.006_bib0155","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jnnp-2014-308630","article-title":"MRI pattern in asymptomatic natalizumab-associated PML","volume":"86","author":"Wattjes","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.tips.2015.09.006_bib0160","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.24153","article-title":"Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Warnke","year":"2014","journal-title":"Ann. Neurol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614715002059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614715002059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T10:59:34Z","timestamp":1537268374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614715002059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0165614715002059"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2015.09.006","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}